Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-08-31FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for abiraterone acetate from Mylan Pharmaceuticals Inc., enabling a generic version of the cance…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC [Phase 1, Phase 2]
Phase 1/2 trial evaluating LEE011 (ribociclib) in combination with docetaxel and prednisone for metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC [Phase 2]
Phase 2 study evaluating the addition of pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer; results have been p…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating enzalutamide with mifepristone in metastatic hormone-resistant prostate cancer completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment [Phase 2]
Phase 2 trial investigating CRLX101 in combination with enzalutamide for metastatic castration-resistant prostate cancer after prior enzalut…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer [Phase 2]
Open-label Phase II trial of AZD4635 in prostate cancer, including metastatic castration-resistant disease; trial completed with results pos…
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Navarixin in combination with pembrolizumab in adults with selected advanced/metastatic …
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency [Phase 2]
Phase 2 clinical trial update of rucaparib in patients with metastatic castration-resistant prostate cancer and homologous recombination gen…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 study of durvalumab and tremelimumab in chemotherapy-naive metastatic castration-resistant prostate cancer has completed; results we…
-
FDA approval · 2022-05-19FDA Approved: ABIRATERONE ACETATE — Supplemental Application (NORTHSTAR RX LLC)
FDA approved a supplemental application for Abiraterone acetate from Northstar RX LLC, resulting in approval of a generic product under ANDA…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating the combination of testosterone and olaparib in castration-resistant prostate cancer has completed, with results …
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate [Phase 3]
Phase 3 trial update providing long-term safety follow-up and examining long-term exposure to abiraterone acetate in metastatic castration-r…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer [Phase 3]
This clinical trial update notes the completion of a Phase 3 study of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, wi…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 clinical trial evaluating sipuleucel-T in combination with stereotactic ablative body radiation (SABR) for metastatic castration-r…
-
CLINICAL_TRIALS trial_result · 2022-05-05Clinical Trial Update: Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy [Phase 1, Phase 2]
Open-label Phase I/Randomized, Double-Blind Phase II study evaluating AZD5363 in combination with DP chemotherapy for metastatic castration-…
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel [Phase 2, Phase 3]
A completed Phase 2/3 trial update evaluating the optimal sequencing of treatments for poor-risk metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Pamiparib in mCRPC With HRD or BRCA1/2 Mutation [Phase 2]
Phase 2 trial update for pamiparib in metastatic castration-resistant prostate cancer with HRD or BRCA1/2 mutation.
-
FDA approval · 2022-03-28FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Florida Pharmaceutical Products, LLC.)
The FDA approved a supplemental application for Abiraterone Acetate (generic) submitted by Florida Pharmaceutical Products, LLC.
-
FDA approval · 2022-03-24FDA Approved: YONSA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's supplemental application for YONSA (abiraterone acetate), a prostate cancer therapy. The approval authoriz…
-
FDA approval · 2022-03-23FDA Approved: PLUVICTO — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved Pluvicto (lutetium Lu-177 vipivotide tetraxetan) from Novartis as an original approval for metastatic castration-resistant …
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies [Phase 2]
Phase 2 trial update reporting efficacy and safety data for Niraparib in men with metastatic castration-resistant prostate cancer and DNA-re…
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial comparing Abiraterone Acetate tablets with ZYTIGA in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation [Phase 2]
Phase 2 study evaluating olaparib in newly diagnosed metastatic castration-resistant prostate cancer patients with HRR gene mutations.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic [Phase 2]
Phase 2 trial evaluating treatment of metastatic castration-resistant prostate cancer using circulating tumor cell kinetics.